Direct Observation of the Interconversion of Normal and Toxic Forms of α-Synuclein  by Cremades, Nunilo et al.
Direct Observation of the
Interconversion of Normal
and Toxic Forms of a-Synuclein
Nunilo Cremades,1 Samuel I.A. Cohen,1 Emma Deas,2 Andrey Y. Abramov,2 Allen Y. Chen,1 Angel Orte,1,3
Massimo Sandal,1 Richard W. Clarke,1 Paul Dunne,1 Francesco A. Aprile,1,4 Carlos W. Bertoncini,1,5 Nicholas W. Wood,2
Tuomas P.J. Knowles,1 Christopher M. Dobson,1,* and David Klenerman1,*
1Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW, UK
2Department of Molecular Neuroscience, University College London, Institute of Neurology, Queen Square, London WC1N 3BG, UK
3Department of Physical Chemistry, Faculty of Pharmacy, University of Granada, Campus Cartuja, 18071 Granada, Spain
4Department of Biotechnology and Biosciences, University of Milano-Bicocca, Piazza della Scienza 2, 20126 Milan, Italy
5Institute for Research in Biomedicine, Baldiri Reixac 10, 08028 Barcelona, Spain
*Correspondence: cmd44@cam.ac.uk (C.M.D.), dk10012@cam.ac.uk (D.K.)
DOI 10.1016/j.cell.2012.03.037Open access under CC BY license.SUMMARY
Here, we use single-molecule techniques to study
the aggregation of a-synuclein, the protein whose
misfolding and deposition is associated with Parkin-
son’s disease. We identify a conformational change
from the initially formed oligomers to stable, more
compact proteinase-K-resistant oligomers as the
key step that leads ultimately to fibril formation.
The oligomers formed as a result of the structural
conversion generate much higher levels of oxidative
stress in rat primary neurons than do the oligomers
formed initially, showing that they are more
damaging to cells. The structural conversion is
remarkably slow, indicating a high kinetic barrier for
the conversion and suggesting that there is a signifi-
cant period of time for the cellular protective
machinery to operate and potentially for therapeutic
intervention, prior to the onset of cellular damage. In
the absence of added soluble protein, the assembly
process is reversed and fibrils disaggregate to form
stable oligomers, hence acting as a source of cyto-
toxic species.
INTRODUCTION
a-synuclein (aS) is a 140 residue protein expressed abundantly in
the brain, where it can account for up to 1% of all proteins in
the neuronal cytosol (Bonini and Giasson, 2005). It does not
appear to be an essential protein (Abeliovich et al., 2000) and
has multiple proposed functions interacting specifically with
numerous proteins involved in signal transduction, vesicular
trafficking, synaptic behavior, the regulation of oxidative stress,
and mitochondrial function (Bonini and Giasson, 2005). It is,
however, the major constituent of intracellular protein-rich inclu-
sions, Lewy bodies and Lewy neurites, the hallmark lesions1048 Cell 149, 1048–1059, May 25, 2012 ª2012 Elsevier Inc.of Parkinson’s disease (PD) (Spillantini et al., 1998). These
inclusions share common structural characteristics, including
a high b sheet content and a distinctive cross-b X-ray diffraction
pattern, also observed for fibrillar deposits associated with other
degenerative disorders, including Alzheimer’s disease, and
commonly described as amyloid fibrils (Geddes et al., 1968; Chiti
and Dobson, 2006).
The formation of amyloid fibrils in vitro is a common phenom-
enon and is usuallymonitored throughmeasurements of turbidity
or by means of fluorometric dyes, such as Thioflavin T. These
experiments suggest that fibril formation follows a nucleation-
polymerization model (Jarrett and Lansbury, 1992), where
soluble species undergo a nucleation process that generates
oligomeric species that are then able to grow through further
monomer addition, thereby forming protofilaments and eventu-
ally mature fibrils. The characteristic sigmoidal growth profile
reflects the greater ease of addition of monomers onto existing
aggregates compared with the de novo formation of new oligo-
mers directly from monomers alone. The overall reaction rate
therefore accelerates when significant numbers of aggregates
are present in solution, resulting in an initial lag phase followed
by a growth phase during which the overall conversion is accel-
erated before a plateau region is reached when the monomer
concentration is depleted (Figure 1A). Recently, however, it has
become evident that the kinetics of fibril growth can often be
dominated by secondary nucleation events, such as fibril frag-
mentation (Cohen et al., 2011; Knowles et al., 2009), adding
further elements of complexity to the kinetic process.
Both experimental and theoretical studies of the kinetics of
fibril formation have given important insights into the overall
mechanism of amyloid assembly, but little is known in any detail
about the oligomeric species that not only represent the crucial
first steps of the self-association process but have also
been implicated as key species in the pathogenesis of protein
misfolding and deposition diseases (Bucciantini et al., 2002;
Kayed et al., 2003; Lashuel et al., 2002; Luheshi et al., 2007;
Tokuda et al., 2010; Winner et al., 2011). A variety of
distinct morphologies of aS oligomers have been observed using
Figure 1. Experimental Protocol
(A) Example of the kinetics of amyloid fibril formation, including hypothetical snapshots of the ensemble of aS species present at different phases of the
aggregation process, wherein the oligomeric species present in the sample are highlighted with red circles.
(B) Schematic representation of the instrument used for smFRET measurements.
(C) Schematic description of the experimental protocol for aggregation experiments. Bursts of fluorescence coincident in both channels indicate the presence of
FRET-positive oligomeric species (marked as asterisks). Noncoincident bursts can be attributed to monomers and are normally much less bright than those
corresponding to oligomers.
(D) Comparison between the kinetics of oligomer formation under bulk conditions obtained by quantitative SEC analysis (red circles; see also Figure S1G) and
from smFRET experiments, after extrapolating the concentrations from sm to bulk conditions (gray squares). The data reported correspond to the mean and
standard errors of two repetitions in the case of the SEC data and five repetitions for the sm data. See Figure S1 for a detailed characterization of the effect of the
fluorophores on aS aggregation.imaging techniques, notably, atomic force microscopy or trans-
mission electron microscopy (see, e.g., Conway et al., 2000;
Ding et al., 2002; Lashuel et al., 2002; Hoyer et al., 2004). Struc-
tural studies on aS oligomers have also been carried out using
FTIR, Raman, CD, and fluorescence spectroscopy (see, e.g.,
Apetri et al., 2006; Goldberg and Lansbury, 2000; Hong et al.,
2008; Nath et al., 2010; Thirunavukkuarasu et al., 2008), which
have revealed the formation of various oligomeric structures
during aS aggregation, consistent with a progressive increase
in b sheet structure occurring concomitantly with the formation
of more ordered aggregates.
In order to define in more detail the types of oligomers formed
during aS fibril formation and the rates at which they develop, it is
necessary to find the means of overcoming the challenges
inherent in studying these heterogeneous and frequently tran-
sient intermediate species. Recently, techniques have been
developed that are able to observe individual molecular species
in solution (Chiou et al., 2009; Kostka et al., 2008; Orte et al.,
2008), and in the present work we describe experimental and
theoretical approaches that enable us to define in microscopicdetail the assembly of aS into amyloid fibrils. As we discuss
below, the results obtained shed new light on the underlying
molecular processes involved in aS oligomerization and fibril
formation and, in conjunction with cell biology experiments,
provide crucial information on their link with pathogenesis.
RESULTS AND DISCUSSION
Single-Molecule Experiments Reveal the Presence of
Distinct Oligomeric Species during aS Fibril Formation
We have previously demonstrated, using a model amyloidoge-
nic protein, that it is possible to quantify the fraction of oligomers
in a sample and estimate their size distribution using the
two-color coincidence detection (TCCD) method in diffusion
single-molecule (sm) fluorescence experiments (Orte et al.,
2008). Here, we have applied the same principles to aS and
have selected residue 90, at the C-terminal end of the central
hydrophobic NAC region of aS, as an appropriate position
to incorporate fluorophores (see Figure S1 available online).
Although this residue has previously been tagged withCell 149, 1048–1059, May 25, 2012 ª2012 Elsevier Inc. 1049
fluorescent probes to investigate the aggregation of aS (Thiruna-
vukkuarasu et al., 2008), we nevertheless compared the aggre-
gation behavior of aS tagged with the two fluorophores used in
the TCCD experiments, Alexa Fluor 488 (AF488) and Alexa Fluor
647 (AF647), to that of the unlabeled protein and established that
the presence of the dye molecules does not alter the funda-
mental features of the aggregation reaction or the appearance
of the resulting fibrillar aggregates (see Extended Experimental
Procedures for details).
We next performed a series of smTCCD experiments at
different time points during the aS aggregation process.
Equimolecular mixtures of aS labeled with either AF488 or
AF647 were incubated under conditions used previously to
form fibrils in vitro (Wood et al., 1999), and aliquots were taken
at a series of time points and then diluted rapidly by a factor of
105 to a final concentration of 500 pM, which is suitable for
sm analysis. In TCCD, the confocal volume is excited by the
overlapped red (633 nm) and blue (488 nm) lasers, and oligomers
are detected as coincident bursts of fluorescence and readily
distinguished from single-label monomers once account is taken
of chance coincidental background events (Orte et al., 2006). In
this way, we were able to estimate the fraction of oligomeric
species along the aS aggregation process, as well as track the
time evolution of their size distribution.
To obtain additional information on the nature of the oligomers
formed in the aggregation process, we explored the use of
intermolecular fluorescence resonance energy transfer (FRET)
measurements. The samples were irradiated by the blue laser
alone (Figure 1B), that is, only AF488-labeled molecules were
excited directly. We observed, however, that the AF647 dye
was excited indirectly by FRET from adjacent AF488 fluoro-
phores within the aggregated species, generating coincident
fluorescence events inboth theAF488andAF647emission chan-
nels (Figures 1C and S2A); monomers, by contrast, can only give
rise to bursts of fluorescence in the AF488 emission channel. This
approach therefore allowed us to quantify the relative number of
oligomeric andmonomeric species in each sample and explore if
there are any differences in the FRET efficiency that would indi-
cate differences in the oligomer structure.
This analysis was then applied to samples taken at different
incubation times during the aggregation reaction, enabling us
to characterize the populations of aS oligomeric species as
a function of their FRET efficiency and size. Because size is
determined indirectly from fluorescence measurements in
confocal single-molecule techniques applied in solution, we refer
to the apparent oligomer size throughout the paper, which is only
an estimate of the real oligomer size, in part due to the different
paths that an oligomer can take through the confocal volume, but
it can be used to determine the differences in relative sizes
between oligomeric species. Based on our previous method
(Orte et al., 2008), we determined the apparent size of aS oligo-
mers by comparing the intensity in the AF488 emission channel
of the fluorescence burst due to a given oligomer with the
average intensity value for the AF488-labeled monomer (fluores-
cence lifetime measurements confirm that there is no detectable
fluorophore quenching in monomers or soluble oligomers; see
Extended Experimental Procedures) after correcting for the
average FRET efficiency of that particular oligomer (see Experi-1050 Cell 149, 1048–1059, May 25, 2012 ª2012 Elsevier Inc.mental Procedures). Both the fraction of oligomers and their
size distribution during aggregation were in very good agree-
ment with those obtained by smTCCD measurements.
A representative set of smFRET results is shown in Figure 2A.
The data have been analyzed to generate two-dimensional (2D)
histograms, in which the distribution of apparent oligomer sizes
is represented as a function of FRET efficiency. Incubation of
monomeric aS under the aggregation-promoting conditions
used here initially results in the formation of a series of small olig-
omers (n% 10) and then, after a period of a few hours, in a wide
distribution of oligomers, ranging in size from dimers to species
containing more than 100 monomers. Despite the highly hetero-
geneous size distribution of the oligomeric species, a relatively
small range of FRET efficiency values is observed. From a visual
inspection of the data (Figure 2B, top), the distribution of FRET
values appears to vary with the size of the oligomers, revealing
two dominant populations, one corresponding to those of small
size with medium FRET values (0.4–0.7) and the other to larger
species with higher FRET values (0.6–0.9). To analyze these
populations in more detail, we classified the oligomers into three
broad size groups, small (2–5 mers), medium (5–15 mers),
and large (15–150 mers) (larger oligomers were excluded
from the analysis, because too few were encountered to
generate significant statistics), and fitted the FRET histograms
for each group as Gaussian distributions (see Extended Experi-
mental Procedures for a detailed description of the method).
Using this classification we detected four distinct distributions
of oligomers, denoted as Asmall, Amed, Bmed, and Blarge, where A
and B are used to distinguish between species with mid- and
high-FRET values, respectively, and the subscripts are used to
distinguish between the different oligomer size groups. Further
examination of the data revealed that the mean and the width
of the FRET distributions for each oligomer group remained
unchanged during the incubation time, allowing the data sets
at the different times to be fitted globally (Figure 2C). To test
the robustness of this approach, five repetitions of the entire
aggregation experiment were carried out, and the same four
populations with almost identical Gaussian parameters defining
their FRET distributions were obtained in each case (see Table 1
and error bars in Figure 3A).
We also analyzed the formation of oligomers at a protein
concentration (6 mM) similar to that found under physiological
conditions (Iwai et al., 1995). Interestingly, the two major
structural types of oligomers detected at a concentration of
70 mM were also found in the experiments carried out at this
lower concentration (Figure S2B), although their absolute levels
were much lower and no fibrils were detectable by transmission
electron microscopy even after 7 days of incubation. Crucially,
this finding suggests that at physiologically relevant concentra-
tions (Iwai et al., 1995), aS is able to form potentially toxic
oligomeric species.
Next, we set up a series of smFRET experiments on samples
diluted in the presence of unlabeled aS and compared the
number and type of oligomers detected with those found in
samples diluted into buffer alone. The relative difference in the
number of oligomers detected in the two cases provides an
estimate of the relative kinetic stabilities of the oligomeric
species upon dilution to single-molecule conditions. We
Figure 2. aS Oligomers Present during Fibril Formation
Aggregation of aS was followed by smFRET at a range of time points during incubation.
(A) 2D plots corresponding to the relative mass distribution of oligomers at different incubation times as a function of apparent oligomer size (x axis) and FRET
efficiency (y axis); for a clearer visualization of the presence of large oligomers, the mass rather than the number distribution is represented.
(B) A representative 2D plot of the number distribution of oligomers after 60 hr of incubation illustrates the size-dependence of the FRET efficiency distributions
(vertical lines corresponding to apparent oligomer sizes of 5- and 15-mer have been added as a visual guide), where twomain FRET oligomer populations can be
identified. The FRET-derived distributions based on small (red bars), medium (green bars), and large (blue bars) classification are plotted on the graph shown
below.
(C) Representative global fits of the four size-derived FRET oligomer distributions to Gaussian functions as the incubation time varies. See also Figure S2.detected the same FRET distributions and comparable numbers
of oligomers in both types of experiments (data not shown), far
from the difference of a factor of 105 expected from the dilution
from bulk to single-molecule conditions if the oligomers were to
dissociate rapidly at pM concentrations.
This assumption was further strengthened by the close agree-
ment between the concentrations of oligomers detected under
bulk conditions by quantitative size-exclusion chromatography
(SEC) and those estimated from our single-molecule experi-
ments and extrapolated to bulk conditions at different incubation
times (Figure 1D). In the SEC analysis under bulk conditions, wewere able to quantify directly the concentrations of oligomers
present at different incubation times by exploiting the high
extinction coefficients of the fluorophores in the visible region
of the spectra (Figure S1G). The mass fraction of soluble aggre-
gates was found at all times to be very low (%5%), in agreement
with a previous report (Conway et al., 2000), and the kinetics of
oligomer formation were in good agreement with extrapolations
from the single-molecule experiments (Figure 1D). The discrep-
ancies at long incubation times between the two set of data
can be attributed to the increasing contribution to the mass
fraction of large oligomers formed at long incubation times,Cell 149, 1048–1059, May 25, 2012 ª2012 Elsevier Inc. 1051
Table 1. Kinetic Analysis of the Formation of DifferentOligomeric
Populations Classified by Apparent Size and FRET Efficiency




Rate (hr1) Lag Time (hr)
Average FRET
Efficiency
Asmall 0.047 ± 0.019 0.2 ± 1.7 0.61 ± 0.02
Amed 0.041 ± 0.013 0.1 ± 1.0 0.53 ± 0.05
Bmed 0.013 ± 0.005 2.7 ± 1.2 0.74 ± 0.03
Blarge 0.013 ± 0.003 3.3 ± 1.4 0.68 ± 0.05
The apparent growth rate and the lag time were obtained from the quan-
tification of each oligomer type obtained by smFRET experiments by
fitting the time dependence of the population of each oligomer class to
the function y =A$ð1 expððx  x0Þ$rÞÞ, where A is the amplitude, r is
the apparent growth rate, and x0 is the lag time. The data and the fits to
this function are plotted in Figure 3A (see Extended Experimental Proce-
dures for a detailed explanation of the analysis). The errors reported for
the kinetic parameters correspond to the fitting errors. The average
FRET efficiency was obtained from a global analysis of the FRET distribu-
tions at the different incubation times (see Figure 2C). The values reported
correspond to the mean and standard error of five repetitions.which were excluded from the analysis in our smFRET experi-
ments because of inefficient sampling of these species.
aS Oligomers Undergo Structural Reorganization prior
to Fibril Growth
We next determined the kinetics of formation of all four types of
oligomers observed in the smFRET experiments (Figure 2C). For
simplicity, we fitted a single-exponential function coupled with
a lag time (Figure 3A); the parameters obtained from the fitting
are shown in Table 1. Oligomers Asmall and Amed show similar
kinetics, as do oligomers Bmed and Blarge (see Table 1), suggest-
ing that the different FRET efficiencies report on two different
structural types of oligomers. A longer lag time was observed
for the formation of type B oligomers, suggesting that these
species could result from a reorganization of type A oligomers,
in agreement with previous suggestions that fibril formation by
aS involves the sequential appearance of discrete oligomeric
intermediates (Conway et al., 2000).
To gain further insight into the different structures of A and B
oligomers, we measured the susceptibility of each to proteinase
K degradation relative to that of themonomeric and fibrillar forms
of the protein. The core of aS fibrils, like that of other amyloid
structures, is highly resistant to proteinase K degradation (Miake
et al., 2002; Neumann et al., 2002). We found that the fibrils
labeled with fluorophores were completely resistant to degrada-
tion when treated with 0.4 mg/ml proteinase K for 20 min at 37C
but were gradually degraded when the proteinase K concentra-
tion was increased from 0.4 to 10 mg/ml (Figure S3B), in agree-
ment with the proteinase K degradation profiles reported
previously for aS fibrils both in vitro and in vivo (Neumann
et al., 2002). In contrast, the monomeric form of the protein is
highly susceptible to degradation in agreement with expecta-
tions in the light of its intrinsically disordered nature.
The resistance to degradation of A- and B-type oligomers was
assessed by smFRET experiments after similar incubations at
increasing proteinase K concentrations (see Extended Experi-
mental Procedures and Figure S3A). By comparing the concen-1052 Cell 149, 1048–1059, May 25, 2012 ª2012 Elsevier Inc.trations of proteinase K at which 50% of each protein species is
degraded (Cm), we can conclude (Figure 3B) that type-A oligo-
mers are as sensitive to proteinase K as the monomeric protein
(Cm = 0.05 ± 0.09 mg/ml, and 0.05 ± 0.01 mg/ml, respectively),
whereas type-B oligomers are substantially more resistant to
degradation (Cm = 0.27 ± 0.02 mg/ml) although not as highly
resistant as the mature amyloid fibril (Cm = 1.1 ± 0.3 mg/ml). As
resistance to proteolytic, and specifically proteinase K, digestion
has been found generally to correlate with the degree of persis-
tent structure and b sheet content of aggregated species
(Kocisko et al., 1995; Miake et al., 2002; Nordstedt et al.,
1994), our results strongly suggest that type-A oligomers lack
persistent structure, although their structure cannot be random,
because they give rise to a distinct FRET peak. In contrast, type-
B oligomers are likely to contain a significant degree of b sheet
structure. This conclusion is in agreement with previous studies
of aS aggregation, where a progressive increase in b sheet
structure was observed during aS aggregation before the forma-
tion of mature amyloid fibrils (Apetri et al., 2006).
Disaggregation of aS Fibrils Leads to the Release
of Oligomeric Species
A number of studies have shown directly or indirectly that
amyloid fibrils are able to disaggregate, for example, as a result
of changes in pH (Picotti et al., 2007) or addition of chemical
denaturants (Calamai et al., 2005; MacPhee and Dobson,
2000). We therefore set out to probe the disaggregation of aS
fibrils under near-physiological conditions by incubating pre-
formed labeled aS fibrils at 37C in monomer-free buffer (see
Experimental Procedures) and carrying out a series of smFRET
experiments over a period of several weeks (Figure 4). There
was greater variability in the data from these experiments than
from the aggregation experiments, an observation attributable
to a significant variability in the degree of maturation of the fibrils
in the different samples. We observed in all cases that, however,
disaggregation results in species with a wide variation in size
(Figure 4), indicating that monomeric, as well as oligomeric,
species detach from the fibrils; after longer incubation times,
however, these oligomers were found to have dissociated into
monomers (see Figures 4, S4A, and S4B). Interestingly, a high
fraction of oligomers formed at the beginning of the disaggrega-
tion experiment possesses FRET efficiencies similar to the
type-B oligomers that are formed in the late stages of aggrega-
tion (see Table S1).
Because standard confocal smFRET techniques applied in
solution have limitations in the detection of large species, we
used single-molecule total internal reflection fluorescence
(smTIRF) experiments to probe further the nature of the aggre-
gates generated by fibril disaggregation and in the late stages
of the aggregation process (see Extended Experimental Proce-
dures and Figures S4C–S4F). Under the latter conditions, two
FRET distributions were observed, corresponding to the two
distributions detected in solution by smFRET experiments
(type A and B), whereas in the fibril disaggregation sample,
at early incubation times, the data showessentially a single distri-
bution at high-FRET efficiencies, corresponding to type-B
oligomers. Thus, the TIRF experiments confirm that fibrils
initially disaggregate largely into type-B oligomers, a finding
Figure 3. Characterization of the Different Oligo-
meric Species Formed during aS Aggregation
and Fibril Formation
(A) The time dependence of the mass fraction of the four
oligomeric distributions Asmall (red squares), Amedium
(orange circles), Bmedium (green triangles), and Blarge (blue
triangles). The data shown correspond to the average and
standard error of five different experiments.
(B) Proteinase K degradation curves of the different
protein species (monomer in red, type A oligomer in
orange, type B oligomer in blue, and fibrils in black). The
data shown here correspond to the average and standard
error of three different experiments. See also Figure S3.that strongly supports the view that the latter possess a b sheet
structure that could resemble that found in the amyloid state.
Moreover, the fact that both types of oligomers are detected in
fibril disaggregation experiments provides further evidence for
a structural conversion between the two types of oligomers and
that such a conversion is likely to be a key step in fibril formation.
Kinetic Analysis of the Early Stages of Amyloid Fibril
Formation
We then set out to determine the rate constants for the reactions
associated with the early stages of aggregation using our
smFRET experiments. For this purpose, we needed a kinetic
model that could explain the following experimental observa-
tions: (1) a lag phase in the formation of fibrils; (2) the presence
of two different structural types of oligomers; and (3) a lag phase
in the appearance of type-B, but not type-A, oligomers.
A general nucleation and growth model can explain the lag
phase observed in bulk aS fibril formation experiments. This
model then needs to include a conformational conversion step
to take account of the two types of oligomeric states observed
during aggregation and of the lag phase for type-B oligomers.
The simplest model that is consistent with these observations
is a nucleation and growth model with a conformational conver-
sion step, analogous to that used to describe the conformational
conversion mechanism suggested for prions (Serio et al., 2000).
We therefore extended the analytical solution that we have
generated to interpret the kinetic rate equations for a nucleation
and growth model (Knowles et al., 2009) by the addition of
a conversion step. As shown in Figure 5A, this model assumes
that primary nucleation results in the creation of oligomers of
type A from monomeric protein molecules. Type-A oligomers
can grow through monomer addition, but they can also convert
into type-B oligomers, indicating that multiple parallel pathways
could result in the formation of type-B oligomers of a given size;
details of the early-time analytical and exact numerical solutions
of the model are presented in the Supplemental Information.
This model was then used to fit the experimental kinetic data
describing the formation of the two types of oligomers over the
first 30 hr of incubation, that is, during the lag phase observed
in the kinetics of formation of fibrils under bulk conditions; as
shown in Figure 5B, the model fits the data well. At later times,
additional events, such as the formation of large fibrillar species,
the contribution of the reverse processes involving conversion of
type-B oligomers into type-A oligomers, and the dissociation of
type-A oligomers, become significant and result in underfitting(see Extended Experimental Procedures). Overall, therefore,
this kinetic description in terms of the dominant events associ-
ated with both fibril formation and disaggregation enables the
data obtained from single-molecule experiments to be under-
stood on the basis of a small number of well-definedmicroscopic
parameters, the values of which can be determined directly from
the experimental data. Thus, the primary nucleation rate constant
for oligomers of type A can be defined as43 108 s1 and the
conversion rate constant from type-A to type-B oligomers as 5
3 106 s1. Note that, because the number of monomeric
species able to participate in primary nucleation greatly exceeds
the number of oligomers that are involved in the structural
conversion, the overall primary nucleation rate is larger than the
conversion rate, a situation that results in the observed build-
up of the type-A oligomers during the aggregation process.
A particularly interesting result is that the rate of structural
conversion between the two types of aS oligomers determined
from the analysis corresponds to a half-time of ca. 35 hr,
a time which is very long compared, for example, with the time
required for the folding of small single-domain globular proteins,
the characteristic times for which range from microseconds to
seconds (Jackson, 1998). The slow rate indicates that the energy
barrier for the conversion from a relatively unstructured oligomer
to a b sheet rich oligomer is very high, an observation that can be
attributed in part to the multiple permutations of interstrand
hydrogen bonding interactions and in part to the fact that the
b sheet rich species are likely to have a significant fraction of their
hydrophobic side chains exposed to the solvent as found in
amyloid fibrils (Heise et al., 2005; Vilar et al., 2008). Furthermore,
previous studies of the folding kinetics of pertactin, a protein that
has an elongated parallel b-helix shape resembling that of an
amyloid fibril, found a half-time for refolding of 3 hr (Junker and
Clark, 2010), only an order of magnitude faster than the rate of
reorganization of oligomeric aS into intermolecular b sheet struc-
tures, suggesting that the intrinsic formation of an amyloid-like
structure proceeds through an energy landscape with significant
barriers between different regions of conformational space, in
contrast to the smooth funnel-like landscape found for the
majority of small naturally evolved proteins (Onuchic et al.,
1997; Dinner et al., 2000).
PK-Resistant Oligomers Induce Higher Aberrant Levels
of ROS in Cells Than Do PK-Sensitive Oligomers
Given the long-standing pathophysiological link between
increased levels of oxidative stress and PD (Jenner and Olanow,Cell 149, 1048–1059, May 25, 2012 ª2012 Elsevier Inc. 1053
Figure 4. aS Fibril Disaggregation
(A) 2D plots of the relative mass distribution of oligomers according to apparent size and FRET efficiency, as explained in Figure 2A.
(B) Representative global fits of the size-derived FRET oligomer distributions as a function of the incubation time. See also Figure S4 and Table S1.1998; Jenner, 2003) and the reported specific generation of intra-
cellular reactive oxygen species (ROS) by aggregating proteins
implicated in neurodegenerative diseases (Tabner et al., 2001;
Parihar et al., 2009), we examined if the production of ROS
changed on exposure of rat primary midbrain neurons to
samples containing different aS species, using samples from
identical aggregation experiments to those described above.
Two samples containing a mixture of monomeric and oligomeric
species with different concentrations of type-A and type-B
oligomers were obtained by taking aliquots of an aggregating
sample at two different incubation times. The first sample was
enriched in type-A oligomers (denoted as the ‘‘oligomer A
sample’’) and was obtained after 20–25 hr of incubation; it
contained ca. 200 nM of type-A oligomers and ca. 50 nM of
type-B oligomers (concentrations are in number of species) in1054 Cell 149, 1048–1059, May 25, 2012 ª2012 Elsevier Inc.the presence of 70 mM of monomers. The second sample
(denoted the ‘‘oligomer B sample’’), taken after 70 hr of incuba-
tion, contained ca. 200 nMof type-A oligomers and ca. 150 nMof
type-B oligomers in the presence of 50 mMof monomers. In both
cases, fibrillar species were removed from the sample by centri-
fugation. In addition, we took an aliquot from the sample before
initiating the aggregation as a monomeric control sample (at
a concentration of 70 mM) and another aliquot at the end of the
aggregation as a fibrillar control sample. The latter was centri-
fuged and the fibrillar material resuspended in the same volume
as that of the initial sample, which contained ca. 200 nM of fibrils
(in number concentration).
We first assessed the ability of cells to take up the different
forms of aS using confocal microscopy; the rate of uptake of
the differently labeled aS species was calculated by measuring
Figure 5. Kinetic Analysis of aS Oligomerization
(A) Scheme for the minimalistic kinetic model used to fit the early stages of aS
aggregation.
(B) Results of the global fitting (continuous lines) of the kinetics of formation of
the two types of oligomeric species estimated under bulk conditions from
smFRET experiments. Data for type A oligomers and type B oligomers are
shown as orange circles and blue squares, respectively (average and standard
error of five different experiments). The vertical dashed line is at 30 hr, corre-
sponding to the lag phase of fibril formation estimated under bulk conditions,
up to which time our model accounts well for the different microscopic
processes governing the aggregation reaction.
(C) Cartoon showing the conversion of an 8-mer of aS from a collapsed to an
ordered proteinase-K-resistant form. Residues of each monomer are colored
according to their location in the amino acid sequence. The average distance
between fluorophores, represented as green and red spheres, is different for
each type of oligomer and hence gives rise to different average FRET effi-
ciencies.
Figure 6. Evaluation of the Pathophysiological Effects of the aS
Species on Rat Primary Neuronal Cultures
(A) Representative traces showing the rate of uptake of the different types of
aS species into the cell body. The fluorescence of AF488-labeled aSwas used
to track monomeric aS uptake, whereas the fluorescence emission of AF647-
labeled aSwas used to follow the uptake of oligomeric and fibrillar forms of the
protein (see also Figure S5), as only these species are able to produce FRET
signals.
(B) Bar chart displaying cytoplasmic (HEt) and mitochondrial (MitoSOX) ROS
production induced in cells after exposure to each aS sample (see ‘‘PK-
Resistant Oligomers Induce Higher Aberrant Levels of ROS in Cells than Do
PK-Sensitive Oligomers’’ section in the main text for a detailed explanation of
the composition of each sample). *p < 0.05; **p < 0.005.
(C) Representative cellular traces showing the slower production of ROS
induced by type B aS oligomeric samples after cellular treatment with ABSEF.
Error bars in (B) and (C) represent SEM.the increase in the fluorescent intensity signal within the cell
body (Figures 6A and S5). We observed a rapid (between
6–8 min) and efficient uptake of all aS species into both neuronsand astrocytes. The exposure of the cells to the aS species
had no detectable effect on cell viability over 24 hr. For the
monomeric protein, the time for maximal uptake reported hereCell 149, 1048–1059, May 25, 2012 ª2012 Elsevier Inc. 1055
corresponds to the time to reach saturation in the quantity
of internalized protein, whereas for oligomeric and fibrillar
species, due to the reduced quantity of these species in the cor-
responding solutions, it represents the time the cells needed to
take up the total number of FRET-positive species added to
the cellular media (see Figure S5).
For cytosolic ROS assessment, cultures were briefly incu-
bated in the presence of hydroethidium (HEt) prior to exposure
to aS samples, whereas cultures were preincubated with Mito-
SOX (the mitochondrially targeted equivalent of HEt) for mito-
chondrial ROS measurements. Exposure of the cultures to
10 ml monomeric or fibrillar aS samples had amarginal and insig-
nificant effect on cytoplasmic and mitochondrial ROS produc-
tion (Figure 6B). By contrast, exposure of the neuronal cultures
to the type-B oligomeric samples, and to a lesser degree to
the type-A oligomeric samples, induced a specific, rapid, and
significant increase in cytoplasmic ROS production (Figures 6B
and 6C; p < 0.05 for type-A oligomeric samples and p < 0.001
for type-B oligomeric samples, respectively). The lack of ROS
production from the mitochondria, which are the primary source
of ROS in cells, suggests that the excessive ROS production
observed in neurons and astrocytes is induced directly by the
oligomeric aS species. In support of this conclusion, application
of 20 mMABSEF, a potent NADPH oxidase inhibitor, which is the
main producer of ROS in both cytosol and mitochondria, was
initially able to delay but not completely block the aberrant
ROS production induced through uptake of the type-B oligo-
meric sample (Figure 6C; n = 67 cells).
Overall, therefore, these experiments show that the PK-resis-
tant aS soluble oligomers induce much higher levels of ROS in
cells than do the PK-sensitive oligomers, suggesting that the
different oligomeric structures have different physiological
effects. Moreover, our results are in excellent agreement with
a recent study of a model protein that showed that only the addi-
tion of oligomers exposing hydrophobic surfaces to the cellular
media resulted in an increase in intracellular ROS production
(Zampagni et al., 2011) and in agreement with previous theoret-
ical and experimental observations in which the degree of hydro-
phobic exposure in oligomeric species has been directly linked
to cellular dysfunction (Bolognesi et al., 2010; Campioni et al.,
2010; Cheon et al., 2007).
Conversion to Proteinase-K-Resistant Oligomers Is the
Key Step in Aggregation
Of particular importance in this study has been the identification
of a slow conversion from the initially formed and readily degrad-
able oligomers to compact and highly structured oligomers that
are likely to contain amyloid-like b sheet structure and have
a significant fraction of the hydrophobic side chains exposed
to the solvent. These latter oligomers induce much higher levels
of ROS in cells than do their precursor oligomers, indicating that
they aremore damaging to cells as aberrant ROS production has
been shown to activate apoptotic cascades that result in the
death of dopaminergic neurons (Jenner and Olanow, 1998; Jen-
ner, 2003). At the same time, increased ROS levels are thought to
accelerate additional aS oligomer formation (Maries et al., 2003),
reflecting the positive feedback between such processes, which
can explain the cascade of events causing the development of1056 Cell 149, 1048–1059, May 25, 2012 ª2012 Elsevier Inc.disease. These results also suggest that the rate of the structural
conversion relative to other biologically relevant processes will
be a crucial factor in controlling the accumulation of damaging
and degradation resistant oligomeric species. It is interesting
to note in this regard that this slow structural conversion is on
the same timescale as the half-life for aS turnover in vivo re-
ported previously (Cuervo et al., 2004; Okochi et al., 2000).
Together with the fact that the initially formed oligomers are
highly degradable, this result indicates that there is a significant
period of time for the cellular protein degradation machinery to
operate and potentially time for therapeutic intervention, prior
to the onset of cellular damage. Our results also indicate that
stable oligomers of aS can be formed at physiologically relevant
concentrations, and once even a relatively small number of
b sheet oligomers are formed and free to react, the aggregation
reactions can be accelerated dramatically. These findings high-
light the key role that molecular chaperones and the cellular
protein degradation machinery must play continually in prevent-
ing damage caused by such oligomers and hence the onset of
disease (Balch et al., 2008; Morimoto, 2008).
When fibrils of aS are incubated in the absence of monomeric
protein molecules, disaggregation occurs to produce the same
type of oligomers as those found in the aggregation reaction,
in particular damaging PK-resistant oligomers, which indicates
that fibrils could act as a source of soluble species that are
potentially pathogenic to neuronal cells and whose concentra-
tions are likely to be high in the vicinity of the fibrils. This conclu-
sion suggests that toxic agents are not generated just in the early
stages of the aggregation process but also as a result of the
disaggregation of amyloid fibrils, a crucial finding that needs to
be taken into account when considering the origin and spread
of neurodegenerative diseases and when designing therapeutic
strategies, especially those based on the disaggregation of
fibrils. Indeed, our results support the hypothesis that fibrils
can act either to sequester misfolded potentially toxic species
(Lansbury, 1999) or, depending on the conditions, to release
them into the local environment, thereby unifying two apparently
distinct views drawn from observations of protein aggregation in
model organisms (Cohen et al., 2006).EXPERIMENTAL PROCEDURES
Sample Preparation
The A90C mutant variant of aS was purified as a monomeric fraction from Es-
cherichia coli as described previously (Hoyer et al., 2002) and labeled with
either maleimide-modified AF488 or AF647 dyes (Invitrogen, Carlsbad, CA,
USA) via the cysteine thiol moiety as previously reported (Thirunavukkuarasu
et al., 2008). The labeled protein was purified from the excess of free dye by
a P10 desalting columnwith SephadexG25matrix (GEHealthcare,Waukesha,
WI, USA), concentrated using Amicon Ultra Centricons (Millipore, Billerica,
MA, USA), divided into aliquots, flash frozen, and stored at 80C. Each
aliquot was thawed immediately and used only once. The degree of mono-
meric protein in the stock solution was assayed by smFRET as described in
the Extended Experimental Procedures.
For the aggregation reactions, equimolecular concentrations of the AF488-
and AF647-labeled A90C aS in Tris 25mM (pH 7.4) and 0.1MNaCl (with 0.01%
NaN3 to prevent bacterial growth during the experiments) were mixed to give
a final volume of 300 ml, bringing the total protein concentration to 1 mg/ml
(70 mM). The solutions were incubated in the dark at 37C, with constant agita-
tion at 200 rpm for 4–8 days, during which time aliquots were taken. At each
time point, a 2 ml aliquot was diluted 105-fold by serial dilution with 0.022 mm-
filtered buffer (Tris 25 mM [pH 7.4] and 0.1 M NaCl) for smFRET analysis at
room temperature. Glass slides were treated by incubation for 1 hr with BSA
at 1 mg/ml to prevent aS aggregates from adsorbing to the surface (as shown
by TIRF, see Extended Experimental Procedures), and immediately after
removal of the BSA solution, 500 ml of diluted sample was placed on the slide
for analysis.
For the disaggregation experiments, fibrils formed from a mixture of protein
labeled with each fluorophore were washed by two cycles of centrifugation
and resuspension in 500 ml of fresh buffer. Then, 300 ml of fresh monomer-
free buffer solution was added to the fibrillar pellet, which was then gently
resuspended and incubated at 37C without shaking for 4 weeks. The total
protein concentration in the fibril disaggregation samples was estimated to
be%1 mM.
Single-Molecule Data Collection and Analysis
The instrumentation used for TCCD and smFRET experiments has been
described in detail previously (Orte et al., 2006). For smFRET, only the
488 nm laser was used to excite the sample (Figure 1B), with a total laser power
of 47.5 mW. PC-implemented multichannel scalar cards (MCS-PCS, Ortec)
were used to collect photon counts from two avalanche photodiode detectors
with 1 ms bin times over 8,000 channels on both MCS cards. Typically, 999
frames of 8,000 ms were collected for a total measurement time of 3 hr per
aliquot. During the measurements, the microscope stage was moved at
a constant scanning rate of 200 mm/sby two orthogonal DC motors
(M-112.IDG, Physik Instrumente) so that the encounter rate does not depend
on the size of the observed species. The photon time traces were analyzed by
first setting an optimized threshold value for each channel under our conditions
of measurement to remove the background noise: a 20 photon/ms bin for the
donor channel and a 10 photon/ms bin for the acceptor channel. We analyzed
the event data to derive the distributions of oligomer sizes and FRET values.
Based on the average intensity from a bluemonomer, the approximate number
of monomers per oligomer event can be extracted after correcting the blue
intensity of the oligomer for the fact that it is reduced by FRET and also taking
into account the fact that 50% of the monomers are donors (confirmed by
TCCD experiments, see Extended Experimental Procedures), using the
following equation:






where IA and IDA correspond to the acceptor fluorescence intensity and to
the donor fluorescence intensity in the presence of acceptor, respectively;
ID_monomer corresponds to the average intensity of donor monomers (ca. 30
counts), and g corresponds to a correction factor that accounts for different
quantum yields and detection efficiencies of the donor and acceptor
(g = 0.26). We chose a relatively large oligomer bin size of five (i.e.,
2–5 mers, 5–10 mers, etc.), both to present and analyze the data.






Because oligomers of a wide distribution of sizes were observed, a signifi-
cant number of oligomer events occupied more than one time bin (1 ms).
For these cases, themaximumbrightness recorded per bin (i.e., the brightness
recorded during 1 ms when the oligomer crosses the center of the confocal
volume) was used to calculate both their size and FRET efficiency. Large
species, that is, those corresponding to events occupying more than five
bins or calculated to be more than 150 mers, were assumed to be fibrillar
species and then were excluded from the analysis.
A full description of the methodology used in this study is presented in the
Extended Experimental Procedures.
Live-Imaging Studies
Confocal images were obtained using a Zeiss 710 vis CLSM equipped with
a META detection system and a 403 oil immersion objective. The 488nmArgon laser line was used to excite AF488-labeled aS and fluorescence
emission collected between 505–550 nm (green channel) and 630–650nm
(red channel). FRET measurements (excitation of AF488 and emission of
AF647) were used to quantify the uptake of oligomeric and fibrillar aS because
monomers are unable to undergo FRET. Illumination intensity was kept to
a minimum (at 0.1%–0.2% of laser output) to avoid phototoxicity and the
pinhole set to give an optical slice of 2 mm. We recorded from a single focal
plane and specifically selected regions within the cell to measure cellular
uptake of labeled aS species. For confirmation, we checked that the recorded
aS signal was intracellular at the end of each experiment by z-stack scanning
and three-dimensional reconstruction using Zeiss software.ROS Measurements
Fluorescence measurements were obtained on an epifluorescence inverted
microscope equipped with a 203 fluorite objective. For HEt and MitoSOX
measurements, a ratio of the oxidized/reduced formwasmeasured: Excitation
at 540 nm and emission recorded above 560 nm were used to quantify the
oxidized form (ethidium), whereas excitation at 360 nm and emission collected
from 405 to 470 was used for the reduced form (hydroethidium). All data
reported in this study were obtained from at least five coverslips and 2–3
different cell and sample preparations.
For measurement of mitochondrial ROS production, cells were preincu-
bated with MitoSOX (5 mM; Molecular Probes, Grand Island, NY, USA) for
10 min at room temperature. For measurement of cytosolic ROS production,
dihydroethidium (2 mM) was present in the solution during the experiment.
No preincubation (‘‘loading’’) was used for dihydroethidium to limit the intracel-
lular accumulation of oxidized products. Animal husbandry and experimental
procedureswere performed in full compliancewith the United KingdomAnimal
(Scientific Procedures) Act of 1986.SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures,
six figures, and one table and can be found with this article online at
doi:10.1016/j.cell.2012.03.037.ACKNOWLEDGMENTS
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